210 related articles for article (PubMed ID: 36183104)
1. Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC.
Becker-Pelster EM; Hahn MG; Delbeck M; Dietz L; Hüser J; Kopf J; Kraemer T; Marquardt T; Mondritzki T; Nagelschmitz J; Nikkho SM; Pires PV; Tinel H; Weimann G; Wunder F; Sandner P; Schuhmacher J; Stasch JP; Truebel HKF
Respir Res; 2022 Oct; 23(1):272. PubMed ID: 36183104
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme.
Pankey EA; Bhartiya M; Badejo AM; Haider U; Stasch JP; Murthy SN; Nossaman BD; Kadowitz PJ
Am J Physiol Heart Circ Physiol; 2011 Mar; 300(3):H792-802. PubMed ID: 21217076
[TBL] [Abstract][Full Text] [Related]
3. Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs.
Evgenov OV; Ichinose F; Evgenov NV; Gnoth MJ; Falkowski GE; Chang Y; Bloch KD; Zapol WM
Circulation; 2004 Oct; 110(15):2253-9. PubMed ID: 15466650
[TBL] [Abstract][Full Text] [Related]
4. Erectile Dysfunction in Heme-Deficient Nitric Oxide-Unresponsive Soluble Guanylate Cyclase Knock-In Mice.
Decaluwé K; Pauwels B; Boydens C; Thoonen R; Buys ES; Brouckaert P; Van de Voorde J
J Sex Med; 2017 Feb; 14(2):196-204. PubMed ID: 28161078
[TBL] [Abstract][Full Text] [Related]
5. Nitric Oxide-Independent Soluble Guanylate Cyclase Activation Improves Vascular Function and Cardiac Remodeling in Sickle Cell Disease.
Potoka KP; Wood KC; Baust JJ; Bueno M; Hahn SA; Vanderpool RR; Bachman T; Mallampalli GM; Osei-Hwedieh DO; Schrott V; Sun B; Bullock GC; Becker-Pelster EM; Wittwer M; Stampfuss J; Mathar I; Stasch JP; Truebel H; Sandner P; Mora AL; Straub AC; Gladwin MT
Am J Respir Cell Mol Biol; 2018 May; 58(5):636-647. PubMed ID: 29268036
[TBL] [Abstract][Full Text] [Related]
6. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
Boerrigter G; Burnett JC
Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
[TBL] [Abstract][Full Text] [Related]
7. Inhaled nitric oxide decreases pulmonary soluble guanylate cyclase protein levels in 1-month-old lambs.
Thelitz S; Bekker JM; Ovadia B; Stuart RB; Johengen MJ; Black SM; Fineman JR
J Thorac Cardiovasc Surg; 2004 May; 127(5):1285-92. PubMed ID: 15115984
[TBL] [Abstract][Full Text] [Related]
8. Cinaciguat, a soluble guanylate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus.
Chester M; Tourneux P; Seedorf G; Grover TR; Gien J; Abman SH
Am J Physiol Lung Cell Mol Physiol; 2009 Aug; 297(2):L318-25. PubMed ID: 19465519
[TBL] [Abstract][Full Text] [Related]
9. Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation.
Evgenov OV; Kohane DS; Bloch KD; Stasch JP; Volpato GP; Bellas E; Evgenov NV; Buys ES; Gnoth MJ; Graveline AR; Liu R; Hess DR; Langer R; Zapol WM
Am J Respir Crit Care Med; 2007 Dec; 176(11):1138-45. PubMed ID: 17872487
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.
Triposkiadis F; Xanthopoulos A; Skoularigis J; Starling RC
Heart Fail Rev; 2022 Nov; 27(6):1991-2003. PubMed ID: 35437713
[TBL] [Abstract][Full Text] [Related]
11. Nitric oxide and heat shock protein 90 activate soluble guanylate cyclase by driving rapid change in its subunit interactions and heme content.
Ghosh A; Stasch JP; Papapetropoulos A; Stuehr DJ
J Biol Chem; 2014 May; 289(22):15259-71. PubMed ID: 24733395
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effects of soluble guanylate cyclase stimulation on pulmonary hemodynamics and emphysema development in guinea pigs chronically exposed to cigarette smoke.
Paul T; Blanco I; Aguilar D; Tura-Ceide O; Bonjoch C; Smolders VF; Peinado VI; Barberà JA
Am J Physiol Lung Cell Mol Physiol; 2019 Aug; 317(2):L222-L234. PubMed ID: 31166128
[TBL] [Abstract][Full Text] [Related]
13. Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension.
Oka M; Karoor V; Homma N; Nagaoka T; Sakao E; Golembeski SM; Limbird J; Imamura M; Gebb SA; Fagan KA; McMurtry IF
Cardiovasc Res; 2007 Jun; 74(3):377-87. PubMed ID: 17346686
[TBL] [Abstract][Full Text] [Related]
14. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension.
Schermuly RT; Stasch JP; Pullamsetti SS; Middendorff R; Müller D; Schlüter KD; Dingendorf A; Hackemack S; Kolosionek E; Kaulen C; Dumitrascu R; Weissmann N; Mittendorf J; Klepetko W; Seeger W; Ghofrani HA; Grimminger F
Eur Respir J; 2008 Oct; 32(4):881-91. PubMed ID: 18550612
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide.
Badejo AM; Nossaman VE; Pankey EA; Bhartiya M; Kannadka CB; Murthy SN; Nossaman BD; Kadowitz PJ
Am J Physiol Heart Circ Physiol; 2010 Oct; 299(4):H1153-9. PubMed ID: 20639220
[TBL] [Abstract][Full Text] [Related]
16. NO-independent, haem-dependent soluble guanylate cyclase stimulators.
Stasch JP; Hobbs AJ
Handb Exp Pharmacol; 2009; (191):277-308. PubMed ID: 19089334
[TBL] [Abstract][Full Text] [Related]
17. The Novel, Clinical-Stage Soluble Guanylate Cyclase Activator BI 685509 Protects from Disease Progression in Models of Renal Injury and Disease.
Reinhart GA; Harrison PC; Lincoln K; Chen H; Sun P; Hill J; Qian HS; McHugh MC; Clifford H; Ng KJ; Wang H; Fowler D; Gueneva-Boucheva K; Brenneman JB; Bosanac T; Wong D; Fryer RM; Sarko C; Boustany-Kari CM; Pullen SS
J Pharmacol Exp Ther; 2023 Mar; 384(3):382-392. PubMed ID: 36507845
[TBL] [Abstract][Full Text] [Related]
18. New Generation of sGC Stimulators: Discovery of Imidazo[1,2-
Vakalopoulos A; Wunder F; Hartung IV; Redlich G; Jautelat R; Buchgraber P; Hassfeld J; Gromov AV; Lindner N; Bierer D; Gries J; Kroh W; Paulsen H; Mittendorf J; Lang D; Becker-Pelster E; Brockschnieder D; Geiss V; Li V; Straub A; Knorr A; Mondritzki T; Trübel H; Raschke M; Schaefer M; Thomas D; Sandner P; Stasch JP; Follmann M
J Med Chem; 2023 Jun; 66(11):7280-7303. PubMed ID: 37040336
[TBL] [Abstract][Full Text] [Related]
19. Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis.
Wang Y; Krämer S; Loof T; Martini S; Kron S; Kawachi H; Shimizu F; Neumayer HH; Peters H
Kidney Int; 2005 Jul; 68(1):47-61. PubMed ID: 15954895
[TBL] [Abstract][Full Text] [Related]
20. Soluble Guanylate Cyclase-Mediated Relaxation in Aortas from Rats with Renovascular Hypertension.
Tawa M; Shimosato T; Nakagawa K; Okamura T; Ohkita M
Pharmacology; 2022; 107(3-4):235-240. PubMed ID: 34929695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
